ArticleAesthetic plastic surgery2026
Effectiveness of a rhGM-CSF-Containing Gel on Promoting Wound Healing After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars: A Prospective, Randomized, Split-Face, and Evaluator-Blinded Clinical Trial.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAtrophic acne scars (AAS) is one of the most common skin sequelae following acne vulgaris. Fractional laser has shown great therapeutic potential in recent years, but there is no recognized wound care standard after laser resurfacing. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown its value in many other acute wounds healing. Here, we investigated the efficacy and safety of topical recombinant human GM-CSF after 1927-nm fractional thulium fiber laser (TFL) in AAS treatment.
methods30 patients were enrolled and treated with TFL, then randomly assigned to rhGM-CSF-containing gel for 7 days or no intervention on each side. Photos, melanin index (MI), erythema index (EI), hydration, transepidermal water loss and improvement of lesions were assessed at 0, 3, 7, 14, 30 and 60 days.
results27 patients finally completed the study. Compared to TFL monotherapy, topical rhGM-CSF-containing gel significantly reduced duration of scabbing and skin erythema, and showed milder EI one week after TFL. MI on the rhGM-CSF side exhibited more pronounced decrease at the first and second months after TFL. Patients reported significant differences in sensations of burning, dryness and scabbing between two sides. Both sides yielded improvements in acne scars relative to baseline assessments, but no difference between them.
conclusionThe combination of TFL and topical rhGM-CSF-containing gel showed significantly superior outcomes, manifesting as accelerated wound healing, improved postoperative patient comfort, and a reduced incidence of post-laser pigmentation. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42410191What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.